17-beta-hydroxysteroid dehydrogenase deficiency historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{17-beta-hydroxysteroid dehydrogenase deficiency}}
{{17-beta-hydroxysteroid dehydrogenase deficiency}}
{{CMG}}; {{AE}}
==Overview==
==Historical Perspective==
17 beta hydroxysteroid dehydrogenase III defiency is initially described in 1971 by [[Saez]] and his colleagues. Patients with [[XY]] [[chromosomes]] usually present at birth with female or [[ambiguous]] [[external genitalia]]. Two important features of this disease are the presence of [[epididymus]], [[vas deferens]], and [[seminal vesicles]] and the progressive [[virilization]] at the time of puberty. To date, At least 20 [[mutations]] have been reported in the 17-beta-HSD type 3 isozyme gene (HSD17B3), localized to [[9q22]]. These are mainly [[missense]]/[[nonsense]] mutations. Genetically, patients can be [[homozygous]] or [[compound heterozygous]].<ref name="pmid17509588">{{cite journal| author=Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA| title=17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite. | journal=Fertil Steril | year= 2008 | volume= 89 | issue= 1 | pages= 228.e13-7 | pmid=17509588 | doi=10.1016/j.fertnstert.2007.02.048 | pmc=2259022 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17509588  }} </ref>
17 beta hydroxysteroid dehydrogenase III defiency is initially described in 1971 by [[Saez]] and his colleagues. Patients with [[XY]] [[chromosomes]] usually present at birth with female or [[ambiguous]] [[external genitalia]]. Two important features of this disease are the presence of [[epididymus]], [[vas deferens]], and [[seminal vesicles]] and the progressive [[virilization]] at the time of puberty. To date, At least 20 [[mutations]] have been reported in the 17-beta-HSD type 3 isozyme gene (HSD17B3), localized to [[9q22]]. These are mainly [[missense]]/[[nonsense]] mutations. Genetically, patients can be [[homozygous]] or [[compound heterozygous]].<ref name="pmid17509588">{{cite journal| author=Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA| title=17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite. | journal=Fertil Steril | year= 2008 | volume= 89 | issue= 1 | pages= 228.e13-7 | pmid=17509588 | doi=10.1016/j.fertnstert.2007.02.048 | pmc=2259022 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17509588  }} </ref>
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 18:15, 9 May 2022

17-beta-hydroxysteroid dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17-beta-hydroxysteroid dehydrogenase deficiency historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective

CDC on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective

17-beta-hydroxysteroid dehydrogenase deficiency historical perspective in the news

Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective

Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency

Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Historical Perspective

17 beta hydroxysteroid dehydrogenase III defiency is initially described in 1971 by Saez and his colleagues. Patients with XY chromosomes usually present at birth with female or ambiguous external genitalia. Two important features of this disease are the presence of epididymus, vas deferens, and seminal vesicles and the progressive virilization at the time of puberty. To date, At least 20 mutations have been reported in the 17-beta-HSD type 3 isozyme gene (HSD17B3), localized to 9q22. These are mainly missense/nonsense mutations. Genetically, patients can be homozygous or compound heterozygous.[1]

References

  1. Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA (2008). "17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite". Fertil Steril. 89 (1): 228.e13–7. doi:10.1016/j.fertnstert.2007.02.048. PMC 2259022. PMID 17509588.

Template:WH Template:WS